ClinConnect ClinConnect Logo
Search / Trial NCT05859854

Cenobamate in Adults With Focal-Onset Seizures

Launched by AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A · May 5, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Cenobamate Real Word Epilepsy Focal Onset Seizure Observational Focal Epilepsy Uncontrolled

ClinConnect Summary

The BLESS Study is a clinical trial looking at a medication called cenobamate for adults who have focal-onset seizures, a type of epilepsy that can be hard to control. This study aims to gather information from clinical practice in Italy to better understand how well cenobamate works, how safe it is, and how well patients tolerate it. The trial is currently recruiting participants who are at least 18 years old and have already tried two other epilepsy medications without success.

To join the study, participants need to have been diagnosed with focal epilepsy that hasn’t been controlled, even after using other treatments. They should also have been taking cenobamate for at least 12 weeks and be able to provide information about their seizures from before starting this medication. During the trial, participants will be asked to share their experiences and may need to complete some questionnaires. Importantly, this study will help doctors learn more about cenobamate's effects in real-world settings, which can ultimately benefit others living with epilepsy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥18 years at the time of cenobamate treatment initiation
  • Male or female patients
  • Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC)
  • Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization
  • Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation
  • Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation.
  • Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study-
  • Exclusion Criteria:
  • Patients diagnosed with familial short-QT syndrome
  • Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate)
  • Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome
  • Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol
  • Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales
  • Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

About Aziende Chimiche Riunite Angelini Francesco S.P.A

Aziende Chimiche Riunite Angelini Francesco S.p.A. is a leading Italian pharmaceutical and healthcare company with a rich heritage in developing innovative therapeutic solutions. Established in the early 20th century, the company specializes in a diverse range of products, including prescription medications, over-the-counter drugs, and consumer health items. Committed to research and development, Angelini leverages cutting-edge scientific advancements to address unmet medical needs across various therapeutic areas. With a strong focus on quality and efficacy, the company collaborates with global partners to enhance patient outcomes and improve healthcare practices worldwide.

Locations

Vicenza, , Italy

Roma, , Italy

Pavia, , Italy

Bari, , Italy

Pozzilli, Isernia, Italy

Torino, , Italy

Conegliano, Treviso, Italy

Catanzaro, , Italy

Roma, , Italy

Udine, , Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported